<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340586</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-087</org_study_id>
    <nct_id>NCT01340586</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis</brief_title>
  <official_title>Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg
      Apixaban in subjects with normal renal function and subjects with end stage renal disease
      (ESRD) maintained with hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose : To provide a clear understanding of the pharmacokinetics of Apixaban in
      subjects with ESRD and to determine the effect of hemodialysis on Apixaban pharmacokinetics .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Plasma Terminal Half-life (T-Half) of BMS-730823</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Dose of Apixaban Recovered in Urine (%UR)</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Renal Clearance (CLR) of Apixaban</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Renal Clearance (CLR) of BMS-730823</measure>
    <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Hemodialysis Clearance (CLD) of Apixaban</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Hemodialysis Clearance (CLD) of BMS-730823</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Apixaban Extracted During Hemodialysis</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula [plasma AUC(2-6) exiting - AUC(2-6) entering] / [AUC(2-6) entering] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of BMS-730823 Extracted During Hemodialysis</measure>
    <time_frame>2 to 6 hours post-dose</time_frame>
    <description>The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula [plasma AUC(2-6)exiting - AUC(2-6)entering] / [AUC(2-6) entering] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Laboratory Marked Abnormalities</measure>
    <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
    <description>ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN &gt; 1.1*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx).
Platelet count (*10^9 cell/L): Low if Platelet Count &lt; 0.85*LLN (if Pre-Rx&lt;LLN: &lt;0.85*Pre-Rx).
Creatine (umol/L=micromoles per Liter): High if Creatine &gt; 1.5*ULN (if Pre-Rx&gt;ULN: &gt;1.33*Pre-Rx).
Calcium, Total (mmol/L): High if Calcium &gt; 1.5*ULN (if Pre-Rx&gt;ULN: &gt;1.33*Pre-Rx).
Potassium, serum (mmol/L): High if Potassium &gt; 1.1*ULN (if Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx; if Pre-Rx&lt;LLN: &gt;ULN).
Phosphorus, Inorganic (mmol/L): Low if Phosphate &lt; 0.85*LLN (if Pre-Rx&gt;ULN: &lt;LLN).
Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase &gt; 1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation</measure>
    <time_frame>From Day 1 to 30 days post study discontinuation</time_frame>
    <description>The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Group A: Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Tablets, Oral, 5 mg, Once, 4 days</description>
    <arm_group_label>Group A: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Tablets, Oral, 5 mg, Twice, 15 days</description>
    <arm_group_label>Group B: Apixaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The signed informed consent form.

          -  Subjects with normal renal function classified based on calculated creatinine
             clearance (CLCr) determined by the cockcroft-gault calculation.

          -  Eligible subjects with ESRD that is maintained with chronic and stable hemodialysis.

        Exclusion Criteria:

          -  Any history of abnormal bleeding or coagulation disorders including those in a first
             degree relative under 50 years of age.

          -  History of significant head injury within the last two years.

          -  Any gastrointestinal surgery that could impact the absorption of study drug.

          -  Not expected to continue the hemodialysis treatment for the duration of the study.

          -  INR, PT, or aPTT above the upper limit of normal, unless agreed upon between the
             investigator and BMS medical monitor.

          -  History of allergy to Apixaban or Factor Xa inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22.</citation>
    <PMID>26331581</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <results_first_submitted>March 29, 2016</results_first_submitted>
  <results_first_submitted_qc>August 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2016</results_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PHARMACOKINETIC</keyword>
  <keyword>NOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 18 participants were enrolled in this study. 16 participants were treated and completed the study. Two participants were enrolled but not treated (one withdrew consent, one enrolled as alternate).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Renal Function</title>
          <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
        </group>
        <group group_id="P2">
          <title>ESRD Maintained With Hemodialysis</title>
          <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated participants</population>
      <group_list>
        <group group_id="B1">
          <title>Normal Renal Function</title>
          <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
        </group>
        <group group_id="B2">
          <title>ESRD Maintained With Hemodialysis</title>
          <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="7.7"/>
                    <measurement group_id="B2" value="46.9" spread="7.9"/>
                    <measurement group_id="B3" value="46.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban</title>
        <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban</title>
          <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.6" spread="29"/>
                    <measurement group_id="O2" value="98.9" spread="29"/>
                    <measurement group_id="O3" value="113.6" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose before hemodialysis over Normal Renal Function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.787</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.616</ci_lower_limit>
            <ci_upper_limit>1.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose after hemodialysis over Normal Renal Function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.904</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.697</ci_lower_limit>
            <ci_upper_limit>1.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose before hemodialysis over ESRD Dose after hemodialysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.871</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.723</ci_lower_limit>
            <ci_upper_limit>1.049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823</title>
        <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823</title>
          <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="38"/>
                    <measurement group_id="O2" value="15.9" spread="48"/>
                    <measurement group_id="O3" value="20.0" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban</title>
        <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban</title>
          <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1205" spread="29"/>
                    <measurement group_id="O2" value="1430" spread="41"/>
                    <measurement group_id="O3" value="1673" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose before hemodialysis over Normal Renal Function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.187</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.907</ci_lower_limit>
            <ci_upper_limit>1.553</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose after hemodialysis over Normal Renal Function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.389</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.097</ci_lower_limit>
            <ci_upper_limit>1.758</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose before hemodialysis over ESRD Dose after hemodialysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.855</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.707</ci_lower_limit>
            <ci_upper_limit>1.033</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823</title>
        <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823</title>
          <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="69"/>
                    <measurement group_id="O2" value="746" spread="56"/>
                    <measurement group_id="O3" value="953" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban</title>
        <description>The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban</title>
          <description>The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1265" spread="30"/>
                    <measurement group_id="O2" value="1474" spread="44"/>
                    <measurement group_id="O3" value="1717" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose before hemodialysis over Normal Renal Function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.165</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.880</ci_lower_limit>
            <ci_upper_limit>1.543</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose after hemodialysis over Normal Renal Function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.357</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.066</ci_lower_limit>
            <ci_upper_limit>1.728</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Ratio: ESRD Dose before hemodialysis over ESRD Dose after hemodialysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.858</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.707</ci_lower_limit>
            <ci_upper_limit>1.042</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823</title>
        <description>The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823</title>
          <description>The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
          <population>All treated participants</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">AUC(INF) was excluded due to insufficient profiles</measurement>
                    <measurement group_id="O2" value="NA">AUC(INF) was excluded due to insufficient profiles</measurement>
                    <measurement group_id="O3" value="NA">AUC(INF) was excluded due to insufficient profiles</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban</title>
        <description>Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban</title>
          <description>Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.</description>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="14.45"/>
                    <measurement group_id="O2" value="12.5" spread="3.14"/>
                    <measurement group_id="O3" value="12.7" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Plasma Terminal Half-life (T-Half) of BMS-730823</title>
        <description>Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Terminal Half-life (T-Half) of BMS-730823</title>
          <description>Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.</description>
          <population>All treated participants with ESRD maintained with hemodialysis</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">T-HALF could not be calculated due to a limited number of quantifiable data points on the concentration-time curve</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban</title>
        <description>Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban</title>
          <description>Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.</description>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823</title>
        <description>Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823</title>
          <description>Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.</description>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="6.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="15.00" lower_limit="8.0" upper_limit="60.0"/>
                    <measurement group_id="O3" value="21.00" lower_limit="12.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban</title>
        <description>Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban</title>
          <description>Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.</description>
          <population>All participants with ESRD maintained with hemodialysis</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood entering dialyzer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood exiting dialyzer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823</title>
        <description>Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823</title>
          <description>Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.</description>
          <population>All participants with ESRD maintained with hemodialysis</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood entering dialyzer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood exiting dialyzer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Dose of Apixaban Recovered in Urine (%UR)</title>
        <description>The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Dose of Apixaban Recovered in Urine (%UR)</title>
          <description>The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.</description>
          <population>All treated participants</population>
          <units>percent of dose recovered in urine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.397" spread="8.5545"/>
                    <measurement group_id="O2" value="0.145" spread="0.0881"/>
                    <measurement group_id="O3" value="0.181" spread="0.1391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)</title>
        <description>Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All treated participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)</title>
          <description>Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.</description>
          <population>All treated participants with ESRD maintained with hemodialysis</population>
          <units>percent of dose recovered in dialysate</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.68" spread="1.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Renal Clearance (CLR) of Apixaban</title>
        <description>Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Renal Clearance (CLR) of Apixaban</title>
          <description>Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).</description>
          <population>All treated participants</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.263" spread="44"/>
                    <measurement group_id="O2" value="0.020" spread="70"/>
                    <measurement group_id="O3" value="0.020" spread="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Renal Clearance (CLR) of BMS-730823</title>
        <description>Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).</description>
        <time_frame>24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Renal Clearance (CLR) of BMS-730823</title>
          <description>Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).</description>
          <population>All treated participants</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="62"/>
                    <measurement group_id="O2" value="NA">Parameters cannot be estimated for ESRD group due to functional anuria or below Lower Level of Quantitation (LLOQ)</measurement>
                    <measurement group_id="O3" value="NA">Parameters cannot be estimated for ESRD group due to functional anuria or below Lower Level of Quantitation (LLOQ)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Hemodialysis Clearance (CLD) of Apixaban</title>
        <description>Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All treated participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemodialysis Clearance (CLD) of Apixaban</title>
          <description>Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).</description>
          <population>All treated participants with ESRD maintained with hemodialysis</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Hemodialysis Clearance (CLD) of BMS-730823</title>
        <description>Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemodialysis Clearance (CLD) of BMS-730823</title>
          <description>Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).</description>
          <population>All participants with ESRD maintained with hemodialysis</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">CLD for BMS-730823 was not determined since concentration in all dialysate samples were below Lower Level of Quantitation (LLOQ)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Apixaban Extracted During Hemodialysis</title>
        <description>The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula [plasma AUC(2-6) exiting - AUC(2-6) entering] / [AUC(2-6) entering] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All treated participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Apixaban Extracted During Hemodialysis</title>
          <description>The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula [plasma AUC(2-6) exiting - AUC(2-6) entering] / [AUC(2-6) entering] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.</description>
          <population>All treated participants with ESRD maintained with hemodialysis</population>
          <units>percentage of apixaban extracted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of BMS-730823 Extracted During Hemodialysis</title>
        <description>The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula [plasma AUC(2-6)exiting - AUC(2-6)entering] / [AUC(2-6) entering] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.</description>
        <time_frame>2 to 6 hours post-dose</time_frame>
        <population>All treated participants with ESRD maintained with hemodialysis</population>
        <group_list>
          <group group_id="O1">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of BMS-730823 Extracted During Hemodialysis</title>
          <description>The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula [plasma AUC(2-6)exiting - AUC(2-6)entering] / [AUC(2-6) entering] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.</description>
          <population>All treated participants with ESRD maintained with hemodialysis</population>
          <units>percentage of BMS-730823 extracted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" spread="25.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban</title>
        <description>The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban</title>
          <description>The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
          <population>All treated participants</population>
          <units>maximum percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="56.59"/>
                    <measurement group_id="O2" value="16.6" spread="10.60"/>
                    <measurement group_id="O3" value="16.8" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban</title>
        <description>The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban</title>
          <description>The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
          <population>All treated participants</population>
          <units>maximum percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="58.31"/>
                    <measurement group_id="O2" value="16.9" spread="10.98"/>
                    <measurement group_id="O3" value="17.4" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban</title>
        <description>The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban</title>
          <description>The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.</description>
          <population>All treated participants</population>
          <units>maximum percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="20.40"/>
                    <measurement group_id="O2" value="7.0" spread="9.62"/>
                    <measurement group_id="O3" value="23.0" spread="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban</title>
        <description>Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Dose Before Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>ESRD Dose After Hemodialysis</title>
            <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban</title>
          <description>Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).</description>
          <population>All treated participants</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.659"/>
                    <measurement group_id="O2" value="1.03" spread="0.491"/>
                    <measurement group_id="O3" value="1.29" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Laboratory Marked Abnormalities</title>
        <description>ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN &gt; 1.1*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx).
Platelet count (*10^9 cell/L): Low if Platelet Count &lt; 0.85*LLN (if Pre-Rx&lt;LLN: &lt;0.85*Pre-Rx).
Creatine (umol/L=micromoles per Liter): High if Creatine &gt; 1.5*ULN (if Pre-Rx&gt;ULN: &gt;1.33*Pre-Rx).
Calcium, Total (mmol/L): High if Calcium &gt; 1.5*ULN (if Pre-Rx&gt;ULN: &gt;1.33*Pre-Rx).
Potassium, serum (mmol/L): High if Potassium &gt; 1.1*ULN (if Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx; if Pre-Rx&lt;LLN: &gt;ULN).
Phosphorus, Inorganic (mmol/L): Low if Phosphate &lt; 0.85*LLN (if Pre-Rx&gt;ULN: &lt;LLN).
Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase &gt; 1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx).</description>
        <time_frame>From 24 hours pre-dose to 72 hours post-dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Marked Abnormalities</title>
          <description>ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN &gt; 1.1*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx).
Platelet count (*10^9 cell/L): Low if Platelet Count &lt; 0.85*LLN (if Pre-Rx&lt;LLN: &lt;0.85*Pre-Rx).
Creatine (umol/L=micromoles per Liter): High if Creatine &gt; 1.5*ULN (if Pre-Rx&gt;ULN: &gt;1.33*Pre-Rx).
Calcium, Total (mmol/L): High if Calcium &gt; 1.5*ULN (if Pre-Rx&gt;ULN: &gt;1.33*Pre-Rx).
Potassium, serum (mmol/L): High if Potassium &gt; 1.1*ULN (if Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx; if Pre-Rx&lt;LLN: &gt;ULN).
Phosphorus, Inorganic (mmol/L): Low if Phosphate &lt; 0.85*LLN (if Pre-Rx&gt;ULN: &lt;LLN).
Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase &gt; 1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx).</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation</title>
        <description>The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.</description>
        <time_frame>From Day 1 to 30 days post study discontinuation</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
          </group>
          <group group_id="O2">
            <title>ESRD Maintained With Hemodialysis</title>
            <description>Participants with End Stage Renal Disease (ESRD) maintained with hemodialysis received two doses of apixaban separated by a washout period of at least 7 days; one oral dose of 5mg apixaban 2 hours prior to hemodialysis on Day 1 of Period 1, and a second oral dose of 5mg apixaban immediately following the hemodialysis session on Day 1, Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation</title>
          <description>The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 until 30 days post discontinuation, up to September 2011 (approximately 3 months)</time_frame>
      <desc>Study initiated: June 2011
Study completed: September 2011
Participants underwent regular laboratory testing and investigator assessment as outlined in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Normal Renal Function</title>
          <description>Healthy participants with normal renal function (calculated creatinine clearance (ClCr) &gt; 80 mL/min) received a single oral dose of 5 mg apixaban on the morning of Day 1.</description>
        </group>
        <group group_id="E2">
          <title>ESRD Dose Before Hemodialysis</title>
          <description>Participants with ESRD received one oral dose of 5 mg apixaban 2 hours prior to hemodialysis on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>ESRD Dose After Hemodialysis</title>
          <description>Participants with ESRD received one oral dose of 5 mg apixaban immediately following the completion of hemodialysis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

